Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 Study of S-524101 in Patients with Perennial Allergic Rhinitis
jRCT2080221872Phase 3
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Aug 2012
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of House dust mite allergen extract in perennial rhinitis and allergic rhinitis (AR), sponsored by Shionogi & Co., Ltd.
02
Drugs
House dust mite allergen extract
03
Conditions
perennial rhinitisallergic rhinitis (AR)
Beyond the preview
Go deeper on jRCT2080221872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221872.